Lesson 8 of 9 · 18 min

Parkinson's disease and Alzheimer's disease

Explain how interference in dopamine function in Parkinson's disease and in acetylcholine function in Alzheimer's disease leads to their symptoms, and how treatments act on those neurotransmitters.

What you will be able to do

  • Explain the cause of Parkinson's disease (loss of dopamine neurons in the substantia nigra) and how reduced dopamine in the basal ganglia produces its symptoms.
  • Explain the brain changes of Alzheimer's disease (plaques, tangles, neuron loss, reduced acetylcholine) and how they produce its symptoms.
  • Explain how levodopa, dopamine agonists, deep brain stimulation and cholinesterase inhibitors act, and why none is a cure.
  • Recognise beneficial, harmful and unintended consequences of changing neurotransmitter function.

Two common conditions of later life show what happens when a neurotransmitter system fails. In Parkinson's disease, neurons that make dopamine die, and movement becomes slow and shaky. In Alzheimer's disease, neurons die across the brain, including those that make acetylcholine, and memory fades. Each condition's symptoms follow from the jobs of the neurotransmitter and the structures that lose it, and each treatment works by propping up that neurotransmitter.

Note

Talking about these conditions

Many students know someone living with one of these conditions. Use person-first language ("a person with Parkinson's disease") and describe symptoms as the medical sources do. Both conditions vary a lot from person to person.

Parkinson's disease: the cause. Parkinson's disease is caused by the loss of dopamine-producing neurons in the substantia nigra, a small region of the midbrain. These neurons send dopamine to the basal ganglia, which need it to start movements and keep them smooth. Why the neurons die is not known; a combination of genetic changes and environmental factors is thought to be responsible, inherited forms are rare, and the disease becomes more common with age. Symptoms appear only after a large share of these neurons has been lost. Estimates of how many differ by method: from about 30% (counts of neurons in brains, compared with people of the same age without the disease) to about 70% (some medical sources).

Parkinson's disease
PartWhat happens
InterferenceLess dopamine reaches the basal ganglia, so they cannot properly start intended movements or keep them smooth.
Movement symptomsTremor (shaking) of a body part at rest; rigidity (muscle stiffness); bradykinesia (slowness of movement), with difficulty starting; a shuffling walk and moments of "freezing".
Other symptomsLoss of the sense of smell, sleep problems, depression and anxiety, fatigue; memory and thinking problems in some people later.
TreatmentsLevodopa (with carbidopa); dopamine agonists; MAO-B inhibitors; deep brain stimulation; exercise and physiotherapy. There is no cure.

How the treatments act

  1. Levodopa

    Dopamine itself cannot pass from the blood into the brain, but its precursor levodopa (L-dopa) can. The neurons that remain turn it into dopamine, raising the dopamine supply to the basal ganglia. It is given with carbidopa, which stops it being turned into dopamine in the bloodstream, so more of it reaches the brain.

  2. Dopamine agonists

    These drugs bind to dopamine receptors and act as a substitute for dopamine.

  3. MAO-B inhibitors

    These block an enzyme that breaks down dopamine, so the dopamine that is made lasts longer.

  4. Deep brain stimulation

    Electrodes placed in the brain (in the basal ganglia region) deliver small electrical pulses from a pacemaker-like device in the chest. It eases movement symptoms without adding dopamine, and is used when medicines no longer control symptoms well.

Interactive

Parkinson's disease, step by step

A simplified model: raise the share of neurons lost and watch dopamine fall and symptoms appear, then try each treatment.

Worked example

Explain levodopa treatment for Parkinson's disease

  • Complex familiar

A 64-year-old man with Parkinson's disease has a tremor in his right hand at rest and walks slowly with small steps. He is prescribed levodopa with carbidopa. After five years his doctor notices each dose works for a shorter time.

(a) Explain how the cause of Parkinson's disease leads to his symptoms. (b) Explain how levodopa reduces them. (c) Suggest why the medicine works for a shorter time after five years.

3 steps

Try it yourself first, then check the working one step at a time.

Method

  1. Cause (neurons lost, where) → interference (dopamine falls in the basal ganglia) → symptoms → treatment and its limits.

Watch out for

  • Saying levodopa replaces or regrows neurons.

  • Saying the substantia nigra is in the basal ganglia's job description without the dopamine link.

Key idea

Treatments ease symptoms; they do not stop the disease

Levodopa depends on the neurons that are left to make it into dopamine. As more neurons die, each dose works for a shorter time. After years of treatment many people also develop dyskinesias, involuntary twisting movements caused by the swings in dopamine: a beneficial treatment with an unintended consequence.

Why are people with Parkinson's disease given levodopa rather than dopamine itself?

Choose one answer

Alzheimer's disease: the cause. Alzheimer's disease is the most common cause of dementia. Two abnormal proteins build up in the brain: amyloid forms plaques between neurons, and tau forms tangles inside them. Neurons stop working and die, and the cortex shrinks. The damage usually begins in and around the hippocampus, which is why forming new memories is the first thing affected. Among the neurons lost early are those that make acetylcholine and send it to the hippocampus and cortex, so acetylcholine, needed for learning, memory and attention, falls.

Age is the biggest risk factor: it is most common in people over 65. Genes play a part: the APOE ε4 form of one gene increases the risk of the common late-onset disease, and rare inherited forms can cause symptoms in a person's 30s, 40s or 50s.

Alzheimer's disease
PartWhat happens
InterferenceLoss of acetylcholine-producing neurons reduces acetylcholine in the hippocampus and cortex; plaques and tangles disrupt and kill neurons across the brain.
Early symptomsTrouble remembering recent events and conversations, difficulty finding the right words, getting lost or disoriented. Older memories, already stored in the neo-cortex, last longer.
Later symptomsIncreasing confusion, trouble talking and understanding, changes in mood and behaviour that can make the person seem changed in personality, and needing help with daily tasks.
TreatmentsCholinesterase inhibitors (donepezil, rivastigmine, galantamine); memantine; for some people with early disease, anti-amyloid antibodies (in Australia, donanemab and lecanemab, both registered in 2025). There is no cure.

How the treatments act

  1. Cholinesterase inhibitors

    Acetylcholinesterase is the enzyme that breaks down acetylcholine in the synaptic cleft. Blocking it lets the acetylcholine that is still released act for longer, which can ease memory and thinking symptoms for a time in early to mid-stage disease.

  2. Memantine

    Blocks the effects of excessive glutamate, which can damage neurons; used in moderate to severe disease.

  3. Anti-amyloid antibodies

    Donanemab (registered by the TGA in May 2025) and lecanemab (September 2025) remove amyloid plaques and can slow decline a little in early disease, for people with mild symptoms only. They have serious possible side effects, including swelling and bleeding in the brain, and in August 2026 donanemab was expensive, not on the Pharmaceutical Benefits Scheme and of very limited availability (Australian Prescriber, 2026).

Interactive

Alzheimer's disease

A simplified model of acetylcholine neurons lost and the effect of a cholinesterase inhibitor.

Classify each feature as belonging to Parkinson's disease or Alzheimer's disease.

Worked example

Explain a cholinesterase inhibitor for Alzheimer's disease

  • Complex unfamiliar

A woman in the early stage of Alzheimer's disease often forgets conversations from earlier in the day but remembers her childhood clearly. She is prescribed donepezil, a cholinesterase inhibitor.

(a) Explain why her recent memories are affected but her childhood memories are not. (b) Explain, with reference to synaptic transmission, how donepezil could ease her symptoms. (c) Evaluate the claim that donepezil will stop her Alzheimer's disease getting worse.

4 steps

Try it yourself first, then check the working one step at a time.

Method

  1. Link the symptom to the structure damaged first.

  2. Describe the normal synapse, what the disease changes, then what the drug changes.

  3. Evaluate: judge the claim, give reasons, state the limit.

Watch out for

  • Saying donepezil makes more acetylcholine: it slows its breakdown.

  • Agreeing that the drug stops the disease.

Exam tip

Cause, interference, symptoms, treatment

"Explain the impact of interference" questions reward a chain: cause (which neurons are lost, and where) → interference (which neurotransmitter falls, in which structures) → symptoms (that follow from that neurotransmitter's job) → treatment (how it acts on that neurotransmitter, and its limits). Each link earns marks.

Summary

  • Parkinson's disease: dopamine neurons in the substantia nigra die (cause unknown; genetic and environmental factors; more common with age), so less dopamine reaches the basal ganglia.

  • Its symptoms are tremor at rest, rigidity and slow movement, plus loss of smell, sleep problems and depression; they appear only after a large share of these neurons is lost (estimates range from about 30% to 70%).

  • Levodopa (with carbidopa) is made into dopamine by surviving neurons; agonists mimic dopamine; MAO-B inhibitors slow its breakdown; deep brain stimulation eases symptoms without dopamine.

  • Alzheimer's disease: amyloid plaques and tau tangles kill neurons, beginning near the hippocampus; acetylcholine-producing neurons are lost, so acetylcholine falls.

  • Its symptoms start with forgetting recent events and word-finding problems, then confusion, language and personality changes; age and genes (APOE ε4) are risk factors.

  • Cholinesterase inhibitors let acetylcholine last longer; memantine blocks excess glutamate. No treatment for either disease is a cure.

Finished the lesson?

Try the 2 quick checks above and the lesson completes itself, or mark it complete now.

Lesson 8 of 90% read

Save your progress with a free account